Premium
Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
Author(s) -
Kroboth PD,
Smith RB,
Silver MR,
Rault R,
Sorkin MI,
Puschett JB,
Juhl RP
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb02725.x
Subject(s) - triazolam , cmax , pharmacokinetics , aluminium hydroxide , end stage renal disease , hydroxide , dialysis , antacid , medicine , pharmacology , hemodialysis , chemistry , aluminium , receptor , organic chemistry , benzodiazepine
Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminum hydroxide gel, or to alterations in elimination.